Caffeine metabolism in patients with chronic liver disease

References

• Bonati M, Latini R, Galletti F, Young J F, Tognoni G, Garattini S. Caffeine disposition after oral doses. Clin Pharmacol Ther 1993; 32: 98–106
   Google Scholar
• Blanchard J, Sawers S JA. The absolute bioavailability of caffeine in man. Eur J Clin Pharmacol 1993; 24: 93–8
   Google Scholar
• Campbell M E, Grant D M, Inaba T, Kalow W. Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450. in human liver microsomes. Drug Metab Dispos 1993; 15: 237–49
   Google Scholar
• Grant D M, Campbell M E, Tang B K, Kalow W. Biotransformation of caffeine by microsomes from human liver, kinetics and inhibition studies. Biochem Pharmacol 1993; 36: 1251–60
   Google Scholar
• Berthou F, Ratanasavanh D, Riche C, Picart D, Voirin T, Guillouzo A. Comparison of caffeine metabolism by slices, microsomes and hepatocyte cultures from adult human liver. Xenobiotica 1993; 19: 401–17
   Google Scholar
• Arnaud M J. The pharmacology of caffeine. Progr Drug Res 1993; 31: 273–313
   Google Scholar
• Arnaud M J. Metabolism of caffeine and other components of coffe. Caffeine, coffee, and health, S Garattini. Raven Press, New York 1993; 43–95
   Google Scholar
• Butler M A, Iwasaki M, Guengerich F P, Kadlubar F F. Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Biochemistry 1993; 86: 7696–700
   Google Scholar
• Berthou F, Flinois J P, Ratanasavanh D, Beaune P, Riche C, Guillouzo A. Evidence for the involvement of several cytochromes P-450. in the first steps of caffeine metabolism by human liver microsomes. Drug Metab Dispos 1993; 19: 561–7
   Google Scholar
• Fuhr U, Doehmer J, Battula N, Wölfel C, Kudla C, Keita Y, et al. Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered from expression of single cytochrome P450. isoforms. Biochem Pharmacol 1993; 43: 225–35
   Google Scholar
• Gu L, Gonzalez F J, Kalow W, Tang B K. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2. and CYP2E1. Pharmacogenetics 1993; 2: 73–7
   Google Scholar
• Relling M V, Lin J-S, Ayers G D, Evans W E. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2. activities. Clin Pharmacol Ther 1993; 52: 643–58
   Google Scholar
• Tassaneeyakul W, Birkett D J, McManus M E, Tassaneeyakul W, Veronese M E, Andersson T, et al. Caffeine metabolism by human hepatic cytochromes P450: Contribution of 1A2, 2E1. and 3A isoforms. Biochem Pharmacol 1993; 47: 1767–76
   Google Scholar
• Kalow W. Variability of caffeine metabolism in humans. Drug Res 1993; 35: 319–24
   Google Scholar
• Lelo A, Miners J O, Robson R, Birkett D J. Assessment of caffeine exposure: Caffeine content of beverages, caffeine intake, and plasma concentrations of methylxanthines. Clin Pharmacol Ther 1993; 39: 54–9
   Google Scholar
• Kalow W, Tang B-K. Use of caffeine metabolite ratios to explore CYP1A2. and xanthine oxidase activities. Clin Pharmacol Ther 1993; 50: 508–19
   Google Scholar
• Kalow W, Tang B-K. Caffeine as metabolic probe: exploration of the enzyme inducing effect of cigarette smoking. Clin Pharmacol Ther 1993; 49: 44–8
   Google Scholar
• Callahan M M, Robertson R S, Branfman A R, McComish M F, Yesair D W. Comparison of caffeine metabolism in three nonsmoking populations after oral administration of radiolabeled caffeine. Drug Metab Dispos 1993; 11: 211–7
   Google Scholar
• Campbell M E, Spielberg S P, Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Phar Ther 1993; 42: 157–65
   Google Scholar
• Carrier O, Pons G, Rey E, Richard M O, Moran C, Badoual J, et al. Maturation of caffeine metabolic pathways in infancy. Clin Pharmacol Ther 1993; 44: 145–51
   Google Scholar
• Manfredi R L, Vesell E S. Inhibition of theophylline metabolism by long-term allopurinol administration. Clin Pharmacol Ther 1993; 29: 224–9
   Google Scholar
• Lelo A, Kjellen G, Birkett D J, Miners J O. Paraxanthine metabolism in humans: Determination of metabolic partial clearances and effects of allopurinol and cimetidine. J Pharmacol Exper Ther 1993; 248: 315–9
   Google Scholar
• Grant D M, Tang B K, Kalow W. Polymorphic N-acetylation of a caffeine metabolite. Clin Pharmacol Ther 1993; 33: 355–9
   Google Scholar
• Grant D M, Tang B K, Kalow W. A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol 1993; 17: 459–64
   Google Scholar
• Holstege A, Staiger M, Haag K, Gerok W. Correlation of caffeine elimination and Child's classification in liver cirrhosis. Klin Wochenschr 1989; 67: 6–15
   PubMedGoogle Scholar
• Scott N R, Stambuk D, Chakraborty J, Marks V, Morgan M Y. The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease. Br J Clin Pharmacol 1993; 27: 205–13
   Google Scholar
• Marchesini G, Checchia G A, Grossi G, Lolli R, Bianchi G P, Zoli M, et al. Caffeine intake, fasting plasma caffeine and caffeine clearance in patients with liver diseases. Liver 1993; 8: 241–6
   Google Scholar
• Wahlländer A, Mohr S, Paumgartner G. Assessment of hepatic function: comparison of caffeine clearance in serum and saliva during the day and at night. J Hepatol 1993; 10: 129–37
   Google Scholar
• Wahlländer A, Renner E, Preising R. Fasting plasma caffeine concentration. A guide to the severity of chronic liver disease. Scand J Gastroenterol 1993; 20: 1133–41
   Google Scholar
• Child C G, III, Turcotte J G. Surgery and portal hypertension. The liver and portal hypertension, C G Child, IIIeditor. Saunders, Philadelphia 1964; 1–85
   Google Scholar
• Campbell D P, Parker D E, Anagnostopoulos C E. Survival prediction in portacaval shunts: a computerized statistical analysis. Am J Surg 1993; 126: 748–51
   Google Scholar
• Rodopoulos N, Norman A. Determination of caffeine and its metabolites in urine by high performance liquid chromatography and capillary electrophoresis. Scand J Clin Lab Invest 1993; 54: 305–15
   Google Scholar
• Renner E, Wietholz H, Huguenin P, Arnaud M J, Preisig R. Caffeine: a model compound for measuring liver function. Hepatology 1993; 4: 38–46
   Google Scholar
• Branfman A R, McComish M F, Bruni R J, Callahan M M, Robertson R, Yesair D W. Characterization of diaminouracil metabolites of caffeine in human urine. Drug Metab Dispos 1993; 11: 206–10
   Google Scholar
• Tang B K, Grant D M, Kalow W. Isolation and identification of 5-acetylamino-6-formylamino-3-methyluracil as a major metabolite of caffeine in man. Drug Metab Dispos 1993; 11: 218–20
   Google Scholar
• Statland B E, Demas T, Danis M. Caffeine accumulation associated with alcoholic liver disease. N Engl J Med 1993; 295: 110–1
   Google Scholar
• Tsutsumi M, Lasker J M, Shimizu M, Rosman A S, Lieber C S. The intralobular distribution of ethanol-inducible P450IIE1. in rat and human liver. Hepatology 1993; 10: 437–46
   Google Scholar
• Morgan E T, Koop D R, Coon N J. Catalytic activity of cytochrome P-450. isoenzyme 3a isolated from liver microsomes of ethanol-treated rabbits. J Biol Chem 1993; 257: 13951–7
   Google Scholar